ClinicalTrials.gg
CompletedNCT02115139GRAY-BUpdated Nov 8, 2022Results posted

GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases

A Phase 2 interventional study of Ipilimumab in Melanoma and Brain Metastases, sponsored by Grupo Español Multidisciplinar de Melanoma. Completed at 12 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Grupo Español Multidisciplinar de Melanoma · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies testing ipilimumab in Melanoma — 21 open to participants now, 42 under way, 5 of them phase 3. Ipilimumab · Melanoma.

Enrollment
59th of 152
58 · median 30
Started
2014
with 10 others
Phase 2
83 of 155
12 open now
Registered
72nd of 155
by date

Among the 155 studies testing ipilimumab in Melanoma, this one is the 59th largest by enrollment of the 152 interventional ones that give a count, is one of 11 that started in 2014, is one of 83 in phase 2, and was the 72nd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

21 of the 155 studies testing ipilimumab in Melanoma are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing ipilimumab in Melanoma, or all of them as a file.
02

Study summary

Ipilimumab adds a clinical benefit to radiation therapy in patients with melanoma metastatic to the brain.

Melanoma is the third most common cancer causing brain metastases, after cancers of the lung and breast, which appears to reflect the relative propensity of melanoma to metastasize to the central nervous system (CNS). Brain metastases are responsible for 20 to 54 percent of deaths in patients with melanoma, and among those with documented brain metastases, these lesions contribute to death in up to 95 percent of cases, with an estimated median overall survival ranging between 1.8 and 10.5 months, depending upon other prognostic factors.

Ipilimumab is an anti-Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) monoclonal antibody that has demonstrated a clinically relevant and statistically significant improvement in overall survival, either alone (second line) or in combination with dacarbazine (DTIC) in 1st line.

Ipilimumab has shown activity against brain metastases.

According to the European Medicines Agency (EMA) approved label for Yervoy®, the use of glucocorticoids at baseline (commonly prescribed when brain metastases are diagnosed) should be avoided before the administration of ipilimumab. Data show that the use of even high doses of glucocorticoids for the management of immune-related adverse events do not decrease the efficacy of Yervoy®. There is no documented experience on the efficacy of Yervoy® when given concomitantly with radiation therapy and glucocorticoids.

In experimental models, radiation therapy is synergistic to anti-Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) strategies (abscopal effect).

There are no published results from clinical trials on the interaction between radiation therapy and ipilimumab.

03

Conditions studied

  • Melanoma
  • Brain Metastases

Keywords

  • melanoma
  • brain
  • metastases
  • Patients with melanoma and brain metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give written .
  2. Histologic diagnosis of melanoma.
  3. First episode of radiological evidence of
  4. Be over the age of 18 years old
  5. Radiation Therapy Oncology Group-recursive partitioning analysis (RTOG-RPA) class 2
  6. performance status (PS) more than 70%
  7. Barthel Index of Activities of Daily Living more than 10
  8. (mWHO criteria).
  9. Adequate organ function as determine by the following criteria:

    • White blood count (WBC) more or equal to 2000/ microliter (uL)
    • (ANC) more than 1.5 x 109/L.
    • count more than 75 x 109/L.
    • more than 9 g/dL. If the patient received a red blood count (RBC) transfusion, the required value of hemoglobin should be met at least 1 week after the most recent transfusion.
    • Serum creatinine less or equal to 2.0 x (ULN).
    • Serum (AST) and serum alanine aminotransferase (ALT) less or equal to 2.5 x ULN for patients without liver , or less or equal to 5 times for liver metastases.
    • Total less or equal 2.0 x ULN, (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
  10. Persons of must agree to use an adequate method of throughout treatment and for at least 26 weeks after ipilimumab is stopped

Exclusion criteria

Exclusion Criteria:

  1. Patients with melanoma and with any of the following disease-specific characteristics:

    • Documented evidence of prior progression of melanoma to an ipilimumab-containing regimen (i.e. received at least 2 doses of ipilimumab for either advanced disease or in the setting and the disease progressed/ (according to mWHO criteria) within 24 weeks since the first dose of ipilimumab)
    • Prior radiation therapy to the brain
    • Other prior antineoplastic therapies for brain metastases.
    • Patients with cerebral as the only location of the disease, for which local therapy (neurosurgery, radiosurgery) could achieve a disease-free status
    • Patients with a rapid clinical deterioration, or with risk of herniation, or who require unstable ascending dosing of supportive medication in the last week -including anti-convulsivants, and analgesics-, or who require dexamethasone more than 16 mg/d (or other glucocorticoid at an equipotent dose), or with a high lactate dehydrogenase (LDH) more than 2 x .
  2. Any other form which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, or incidental prostate cancer.
  3. Uncontrolled diabetes mellitus ( more than 9 %)
  4. disease other than vitiligo or past thyroiditis under substitutive hormone therapy: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [eg, Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome and Myasthenia Gravis).
  5. Other chronic intestinal diseases associated with diarrhea.
  6. Active infection or other serious illness or medical condition.
  7. Known active or chronic infection with , , or .
  8. Concomitant therapy with any of the following: interleukin-2 (IL-2), interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; agents; other investigation therapies; or chronic use of systemic corticosteroids (used for the management of non-cancer related illnesses), either concomitantly or during the last 30 days prior to the beginning of the treatment.
  9. Any experimental therapy administered in the past 30 days prior to the beginning of the treatment.
  10. Any non-oncology vaccine therapy used for the prevention of infectious diseases (for up to 4 weeks prior to or after any dose of blinded study drug) (see definitions in protocol text)
  11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious) illness.
  12. Any other general, medical or psychological conditions which in the opinion of the investigator will make the administration of ipilimumab hazardous, or that would preclude appropriate or compliance with the protocol, or obscure the interpretation of eventual adverse events (AEs).
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Ipilimumab

    Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1

    Drug: Ipilimumab

Interventions

  • Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles

    Also known as: Experimental

06

What researchers measure

Primary outcomes

  1. 1-year Survival Rate

    During treatment period, there will be assessments every cycle. After end of treatment every 3 month.

    Time frame: From date of inclusion until the date of first documented date of death from any cause, assessed every 3 weeks during for the first 6 months, then every 3 months. Up to 1 year

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Median time from treatment initiation to progression of disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.

  2. Intracranial PFS

    median, 6-month PFS rate

    Time frame: Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.

  3. Extracranial PFS

    median, 6-month PFS rate

    Time frame: Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.

  4. Overall Survival

    median value for OS estimated by kaplan meier method

    Time frame: From date of inclusion until the date of first documented date of death from any cause, assessed every 3 weeks during for the first 6 months, then every 3 months.

  5. Response Rate

    Measured according to Who response criteria and Immune-related response criteria. Response for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.

  6. Adverse Event Rates

    Number of patients with at least one treatment-related toxicity, classified by grade.

    Time frame: From date of inclusion until the date of first documented date of death from any cause or end of study, assessed every 3 weeks during for the first 6 months, then every 3 months.

  7. Rate of Dose Delays/Reductions and Treatment Exposure.

    Treatment feasibility. Number of patients with treatment delays and reductions, categorized as function of the number of events (reductions/delays)

    Time frame: Expected average of 3 weeks during for the first 6 months, then every 3 months.

Other outcomes

  1. Correlation of Biomarker Expression and PFS.

    Translational study. PFS outcome reported by subgroups according to BRAF mutation status

    Time frame: Within 28 days before start treatment, just before the start treatment, then expected average of 3 weeks for the first 12 weeks

  2. Intrapatient Variation of Quantitative Apparent Diffusion Coefficients of Serial Diffusion-weighted Magnetic Resonance Imaging

    Time frame: Baseline and 4 weeks after WBRT

07

Results

Posted Jul 1, 2021

Participant flow

58 patients were enrolled and fulfilled the inclusion criteria, analyzed for safety. During the trial 7 patients discontinued treatment before completion, so the total of patients for efficacy analysis was 51.

Participant flow — Overall Study
MilestoneIpilimumab
Started58
Completed51
Not completed7
Withdrew: Protocol violation1
Withdrew: Treatment discontinuation6

Outcome measures

Primary1-year Survival Rate

During treatment period, there will be assessments every cycle. After end of treatment every 3 month.

Time frame:
From date of inclusion until the date of first documented date of death from any cause, assessed every 3 weeks during for the first 6 months, then every 3 months. Up to 1 year
Reported as:
Number · Percentage of patients alive at 1 year
1-year Survival Rate
Percentage of patients alive at 1 yearIpilimumab
1-year Survival Rate31.8 (18.8 to 44.8)
SecondaryProgression-Free Survival (PFS)

Median time from treatment initiation to progression of disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsIpilimumab
Progression-Free Survival (PFS)3.11 (2.23 to 3.98)
SecondaryIntracranial PFS

median, 6-month PFS rate

Time frame:
Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.

No measurements were reported for this outcome.

SecondaryExtracranial PFS

median, 6-month PFS rate

Time frame:
Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.

No measurements were reported for this outcome.

SecondaryOverall Survival

median value for OS estimated by kaplan meier method

Time frame:
From date of inclusion until the date of first documented date of death from any cause, assessed every 3 weeks during for the first 6 months, then every 3 months.
Reported as:
Median · Months
Overall Survival
MonthsIpilimumab
Overall Survival4.73 (3.59 to 5.87)
SecondaryResponse Rate

Measured according to Who response criteria and Immune-related response criteria. Response for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.
Reported as:
Count of participants · Participants
Response Rate
ParticipantsIpilimumab
modified WHO criteria — Complete Response (CR)2
modified WHO criteria — Partial response (PR)3
modified WHO criteria — Stable disease (SD)12
modified WHO criteria — Progression disease (PD)19
modified WHO criteria — Not evaluable (NE)15
Immun related response criteria (irRC) — Complete Response (CR)2
Immun related response criteria (irRC) — Partial response (PR)3
Immun related response criteria (irRC) — Stable disease (SD)12
Immun related response criteria (irRC) — Progression disease (PD)17
Immun related response criteria (irRC) — Not evaluable (NE)17
SecondaryAdverse Event Rates

Number of patients with at least one treatment-related toxicity, classified by grade.

Time frame:
From date of inclusion until the date of first documented date of death from any cause or end of study, assessed every 3 weeks during for the first 6 months, then every 3 months.
Reported as:
Count of participants · Participants
Adverse Event Rates
ParticipantsIpilimumab
Any grade toxicity — Yes37
Any grade toxicity — No21
Grade 3 or higher toxicity — Yes11
Grade 3 or higher toxicity — No47
SecondaryRate of Dose Delays/Reductions and Treatment Exposure.

Treatment feasibility. Number of patients with treatment delays and reductions, categorized as function of the number of events (reductions/delays)

Time frame:
Expected average of 3 weeks during for the first 6 months, then every 3 months.
Reported as:
Count of participants · Participants
Rate of Dose Delays/Reductions and Treatment Exposure.
ParticipantsIpilimumab
Ipilimumab delay — None43
Ipilimumab delay — 1 event12
Ipilimumab delay — 2 events2
Ipilimumab delay — 3 events1
Ipilimumab delay — 4 events0
Ipilimumab reductions — None50
Ipilimumab reductions — 1 event5
Ipilimumab reductions — 2 events1
Ipilimumab reductions — 3 events1
Ipilimumab reductions — 4 events1
Other pre-specifiedCorrelation of Biomarker Expression and PFS.

Translational study. PFS outcome reported by subgroups according to BRAF mutation status

Time frame:
Within 28 days before start treatment, just before the start treatment, then expected average of 3 weeks for the first 12 weeks
Reported as:
Count of participants · Participants
Correlation of Biomarker Expression and PFS.
ParticipantsIpilimumab
BRAF mutated — Progression disease5
BRAF mutated — No progression12
BRAF mutated — Not applicable34
BRAF native — Progression disease7
BRAF native — No progression19
BRAF native — Not applicable25
Other pre-specifiedIntrapatient Variation of Quantitative Apparent Diffusion Coefficients of Serial Diffusion-weighted Magnetic Resonance Imaging
Time frame:
Baseline and 4 weeks after WBRT

Results for this outcome have not been posted.

Adverse events

Collected over Throughout the study period, from inclusion to 30 days after treatment has ended. Approximately 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ipilimumab40/58 (69%)33/58 (56.9%)57/58 (98.3%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventIpilimumab
DiarrhoeaGastrointestinal disorders6/58
MalaiseGeneral disorders4/58
HeadacheNervous system disorders3/58
Cognitive disturbanceNervous system disorders2/58
FeverGeneral disorders2/58
Lung infectionInfections and infestations2/58
SeizuresNervous system disorders2/58
Thromboembolic eventVascular disorders2/58
Urinary tract infectionInfections and infestations2/58
VomitingGastrointestinal disorders2/58
Most frequent other events
Showing 10 of 13
Most frequent other events
EventIpilimumab
FatigueGeneral disorders28/58
HeadacheNervous system disorders23/58
NauseaGastrointestinal disorders16/58
AnorexiaMetabolism and nutrition disorders15/58
DiarrhoeaGastrointestinal disorders14/58
PruritusSkin and subcutaneous tissue disorders13/58
AlopeciaSkin and subcutaneous tissue disorders9/58
VomitingGastrointestinal disorders9/58
DizzinessNervous system disorders7/58
FeverGeneral disorders7/58

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ipilimumab
Median66 (36.8 to 84.5)
Sex: Female, Male
Sex: Female, Male(Participants)Ipilimumab
Female22
Male36
Region of Enrollment
Region of Enrollment(Participants)Ipilimumab
Spain58
Karnofsky performance status (KPS)
Karnofsky performance status (KPS)(Participants)Ipilimumab
90-10042
70-8015
Not evaluable (NE)1
Barthel index
Barthel index(Participants)Ipilimumab
Lower than 152
15-2056
BRAF mutational status
BRAF mutational status(Participants)Ipilimumab
Mutated20
Native30
Not evaluated (NE)8
Number of previous treatment lines
Number of previous treatment lines(Participants)Ipilimumab
No previous lines29
1 previous line20
2 or more previous lines9
Number of brain metastasis
Number of brain metastasis(Participants)Ipilimumab
Single brain lesion14
Multiple brain lesions43
Not especified (NE)1

2 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • ICO Badalona
    Badalona, Spain
  • H. Clinic de Barcelona
    Barcelona, Spain
  • Hospital Vall d'Hebron
    Barcelona, Spain
  • H. Insular de Canarias
    Las Palmas de Gran Canaria, Spain
  • H. U. Gregorio Marañón
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Clínica Universidad de Navarra
    Pamplona, Spain
  • H. Clínico de Santiago
    Santiago de Compostela, Spain
  • H.U. Virgen Macarena
    Sevilla, Spain
  • H. Virgen de la Salud
    Toledo, Spain
  • H. General de Valencia
    Valencia, Spain
  • Instituto Valenciano de Oncología
    Valencia, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Dec 2016, 32 months.

Results were first posted in Jul 2021, 4 years 6 months after primary completion.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 32 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2014
First posted
Apr 15, 2014
StartActual
Apr 4, 2014
Primary completionActual
Dec 31, 2016
CompletionActual
Jul 31, 2018
Results first posted
Jul 1, 2021
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02115139
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Responsible party
Sponsor
First posted
Apr 15, 2014
Start date
Apr 4, 2014
Primary completion
Dec 31, 2016
Completion
Jul 31, 2018
Results posted
Jul 1, 2021
Last update
Nov 8, 2022

Study contacts

José A López-Martín, MD
study chair · Hospital Universitario 12 de Octubre - GEM

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ipilimumab

Start the discussion